UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Holdings in Ultragenyx Pharmaceutical Inc. $RARE

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 25.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 167,226 shares of the biopharmaceutical company’s stock after selling 55,822 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.17% of Ultragenyx Pharmaceutical worth $5,584,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in RARE. Creative Planning bought a new stake in Ultragenyx Pharmaceutical during the second quarter valued at $454,000. American Century Companies Inc. bought a new position in Ultragenyx Pharmaceutical in the 2nd quarter worth about $366,000. M&T Bank Corp increased its stake in Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 1,192 shares during the last quarter. Amundi raised its holdings in shares of Ultragenyx Pharmaceutical by 1,560.4% in the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after acquiring an additional 93,189 shares in the last quarter. Finally, Jump Financial LLC boosted its position in shares of Ultragenyx Pharmaceutical by 19.5% during the 2nd quarter. Jump Financial LLC now owns 31,673 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 5,158 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at $2,325,654.44. The trade was a 1.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Corsee Sanders sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. The trade was a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 4,060 shares of company stock worth $99,106. 5.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Down 2.7%

NASDAQ RARE opened at $14.88 on Wednesday. The company has a 50-day simple moving average of $27.09 and a two-hundred day simple moving average of $24.93. Ultragenyx Pharmaceutical Inc. has a 12-month low of $13.81 and a 12-month high of $39.89. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -2.55 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same quarter in the previous year, the business earned ($1.17) earnings per share. The company’s quarterly revenue was up 28.5% on a year-over-year basis. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the topic of several research analyst reports. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, September 3rd. TD Cowen cut their price target on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. William Blair lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Thursday, September 3rd. Finally, The Goldman Sachs Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.63.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.